OCT Angiography in Vitreo and Chorioretinal Pathologies
Sponsor
CRG UZ Brussel (Other)
Overall Status
Unknown status
CT.gov ID
NCT03390205
Collaborator
(none)
100
12.9
Study Details
Study Description
Brief Summary
In many diseases of the vitreo and chorioretinal complex, perfusion changes have a diagnostic, prognostic or causative role. The visualisation of perfusion was limited to invasive techniques, which were only to depict vasculature in one plane. Optical coherence tomography is able to visualise and quantify eye perfusion layer-specific and non-invasive.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
100 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Optical Coherence Tomography Angiography in Vitreo and Chorioretinal Pathologies Under the Influence of Dark and Light Adaptation
Anticipated Study Start Date
:
Feb 1, 2018
Anticipated Primary Completion Date
:
Dec 1, 2018
Anticipated Study Completion Date
:
Mar 1, 2019
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Patients
|
Diagnostic Test: Optical coherence tomography angiography under dark and light adaptation
Optical coherence tomography angiography under dark and light adaptation with pupil dilatation
|
| Controls
|
Diagnostic Test: Optical coherence tomography angiography under dark and light adaptation
Optical coherence tomography angiography under dark and light adaptation with pupil dilatation
|
Outcome Measures
Primary Outcome Measures
- Vessel density [5 minutes after intervention ends]
Vessel density measurements of macula and optic nerve
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 85 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
- Patient with vitreo and chorioretinal pathology, aged-adapted controls
Exclusion Criteria:
- Minors, concomitant ocular pathologies, pregnancy, contra-indication for tropicamide
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- CRG UZ Brussel
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Pieter Nelis,
PhD Candidate,
CRG UZ Brussel
ClinicalTrials.gov Identifier:
NCT03390205
Other Study ID Numbers:
- 2812201748151
First Posted:
Jan 4, 2018
Last Update Posted:
Jan 4, 2018
Last Verified:
Dec 1, 2017
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No